Taya V Glotzer1, Paul D Ziegler2. 1. Hackensack University Medical Center, Hackensack, New Jersey,. Electronic address: TayaVG@aol.com. 2. Cardiac Rhythm Disease Management Division, Medtronic Inc, Mounds View, Minnesota.
Abstract
BACKGROUND: Stroke without an identifiable cause is frightening to patients and their families and is frustrating for the caring physician. Approximately 30% of patients with cardiac implanted electronic devices have some evidence of atrial fibrillation (AF), and much of it is silent: asymptomatic, and previously unrecognized. OBJECTIVE: The purpose of this review is to examine "silent AF" as a potential cause of cryptogenic stroke. METHODS/ RESULTS: We begin by reviewing most of the published literature on screening for AF with different monitoring technologies in the setting of cryptogenic stroke. We present the results of 2 recent large randomized trials, CRYSTAL AF and EMBRACE, which compare standard of care monitoring in cryptogenic stroke patients to invasive and noninvasive monitoring strategies, respectively. Finally, we review the relationship of silent AF to stroke in the cardiac implanted electronic device population. Patient selection, duration of monitoring, sensitivity and specificity of monitoring technology, patient compliance, and several other factors affect the yield of AF detection during monitoring. CONCLUSION: Data suggest that silent AF is identified in approximately 30% of cryptogenic stroke patients and has important therapeutic implications. Oral anticoagulation likely should be prescribed when silent AF is detected.
BACKGROUND:Stroke without an identifiable cause is frightening to patients and their families and is frustrating for the caring physician. Approximately 30% of patients with cardiac implanted electronic devices have some evidence of atrial fibrillation (AF), and much of it is silent: asymptomatic, and previously unrecognized. OBJECTIVE: The purpose of this review is to examine "silent AF" as a potential cause of cryptogenic stroke. METHODS/ RESULTS: We begin by reviewing most of the published literature on screening for AF with different monitoring technologies in the setting of cryptogenic stroke. We present the results of 2 recent large randomized trials, CRYSTAL AF and EMBRACE, which compare standard of care monitoring in cryptogenic strokepatients to invasive and noninvasive monitoring strategies, respectively. Finally, we review the relationship of silent AF to stroke in the cardiac implanted electronic device population. Patient selection, duration of monitoring, sensitivity and specificity of monitoring technology, patient compliance, and several other factors affect the yield of AF detection during monitoring. CONCLUSION: Data suggest that silent AF is identified in approximately 30% of cryptogenic strokepatients and has important therapeutic implications. Oral anticoagulation likely should be prescribed when silent AF is detected.
Authors: Barbara Ratajczak-Tretel; Anna Tancin Lambert; Henriette Johansen; Bente Halvorsen; Vigdis Bjerkeli; David Russell; Else Charlotte Sandset; Hege Ihle-Hansen; Erik Eriksen; Halvor Næss; Vojtech Novotny; Andrej Netland Khanevski; Thomas C Truelsen; Titto Idicula; Karen L Ægidius; Håkon Tobro; Siv B Krogseth; Håkon Ihle-Hansen; Guri Hagberg; Christina Kruuse; Kathrine Arntzen; Grete K Bakkejord; Maja Villseth; Ingvild Nakstad; Guttorm Eldøen; Raheel Shafiq; Anne Gulsvik; Martin Kurz; Mehdi Rezai; Jesper Sømark; Stein-Helge Tingvoll; Christine Jonassen; Susanne Ingebrigtsen; Linn Hofsøy Steffensen; Christine Kremer; Dan Atar; Anne Hege Aamodt Journal: Eur Stroke J Date: 2019-03-19
Authors: Hisaki Makimoto; Muhammed Kurt; Michael Gliem; John-Ih Lee; Jan Schmidt; Patrick Müller; Lukas Clasen; Christoph Brinkmeyer; Dong-In Shin; Sebastian Jander; Malte Kelm; Alexander Fürnkranz Journal: J Am Heart Assoc Date: 2017-11-29 Impact factor: 5.501
Authors: Yuichiro Yano; Philip Greenland; Donald M Lloyd-Jones; Emile G Daoud; Jodi L Koehler; Paul D Ziegler Journal: PLoS One Date: 2016-02-16 Impact factor: 3.240
Authors: Gregory W Albers; Richard A Bernstein; Johannes Brachmann; John Camm; J Donald Easton; Peter Fromm; Shinya Goto; Christopher B Granger; Stefan H Hohnloser; Elaine Hylek; Amir K Jaffer; Derk W Krieger; Rod Passman; Jesse M Pines; Shelby D Reed; Peter M Rothwell; Peter R Kowey Journal: J Am Heart Assoc Date: 2016-03-15 Impact factor: 5.501